BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

INX-189: Preliminary Phase Ib data

Preliminary data from 19 evaluable treatment-naïve patients with HCV genotype 1 infection in the first 2 monotherapy cohorts of an ongoing, 2-part, double-blind, U.S. Phase Ib trial showed that once-daily 9 and 25 mg INX-189 significantly reduced mean HCV...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >